MaaT013

MaaT Pharma announced positive Phase 3 ARES study results for MaaT013 in treating GI-aGvHD, showing a 62% GI-ORR at 28 days, surpassing the 38% expected rate. This marks a breakthrough in third-line treatment, offering hope for patients with limited options. MaaT013's efficacy and safety profile support its potential as a first-in-class treatment, with regulatory submission aimed for mid-2025.

MaaT Pharma announced positive Phase 3 trial results for MaaT013, showing a 62% GI-ORR at 28 days in treating GI-aGvHD, surpassing the expected 38%. This marks a significant advancement for third-line GI-aGvHD treatment, offering new hope for patients with limited options.

MaaT Pharma SA's Phase 3 ARES study showed MaaT013 achieved a 62% GI-ORR in third-line GI-aGvHD treatment, surpassing the 38% expectation. With a 54% 12-month survival rate, MaaT013 offers significant survival benefits. MaaT Pharma plans EMA submission by mid-2025 and U.S. Phase 3 trial in 2025, continuing its Early Access Program globally.

MaaT013 demonstrated a 62% gastrointestinal overall response rate at Day 28 in a Phase 3 trial for third-line GI-aGvHD treatment, surpassing the expected 38%. It showed a 54% 1-year survival probability, with plans for European MAA submission by mid-2025. The therapy offers new hope for patients unresponsive to current treatments.

MaaT Pharma's ARES study showed MaaT013 achieved a 62% GI-ORR in third-line GI-aGvHD treatment, surpassing the 38% expectation. With a 54% 12-month survival rate, it offers hope for 3,000 patients annually in the U.S., Canada, and Europe, aiming for EMA submission by mid-2025.

MaaT Pharma announced positive Phase 3 ARES study results for MaaT013 in treating GI-aGvHD, showing a 62% GI-ORR at 28 days, surpassing the 38% expectation. This marks a significant advancement for third-line GI-aGvHD treatment, offering new hope with its first-in-class therapeutic potential. MaaT013's safety and efficacy support its regulatory submission in Europe, aiming for a 2025 EMA application.

MaaT013 demonstrated a 62% gastrointestinal overall response rate at Day 28 in treating GI-aGvHD, surpassing the expected 38%. It showed a 54% 1-year survival probability, indicating potential to improve outcomes for third-line GI-aGvHD patients. MaaT Pharma plans a European MAA submission by mid-2025.

MaaT013 showed a 62% gastrointestinal overall response rate at Day 28 in treating GI-aGvHD, surpassing the 38% expectation. It demonstrated systemic efficacy with 36% complete and 18% very good partial responses. A 54% 1-year survival probability highlights its potential. MAA submission in Europe is anticipated by mid-2025.

MaaT Pharma's MaaT013, a microbiota-based therapy, shows promise in treating acute graft-versus-host disease (aGvHD), with improved survival rates and reduced disease burden in early-access program data. The therapy, especially effective in third-line patients, is undergoing phase 3 trials, aiming for a 2026 market launch.

Seasonal HMPV spike in Beijing raises concerns. MaaT Pharma's Phase III trial succeeds. Viking starts VK2735 Phase II for obesity. Suven begins SUVN-I6107 trial for cognitive disorders. Self-screening may increase cervical cancer cases. Eirion's hair-loss therapy trial shows promise. Insilico's ISM5411 Phase I trials positive. 2025 clinical trials to focus on AI, wearables. Ryght AI and QPS collaborate on trial optimization. MBX reports early success in GLP-1RA trial.